155 related articles for article (PubMed ID: 37819754)
41. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
42. Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis.
Li Z; Yan-Qing W; Xiao Y; Shi-Yi L; Meng-Qin Y; Shu X; Dong-Yong Y; Ya-Jing Z; Yan-Xiang C
J Ovarian Res; 2021 Jan; 14(1):7. PubMed ID: 33413589
[TBL] [Abstract][Full Text] [Related]
43. M1 macrophage-derived exosome-encapsulated cisplatin can enhance its anti-lung cancer effect.
Li J; Li N; Wang J
Minerva Med; 2023 Oct; 114(5):634-641. PubMed ID: 32272830
[TBL] [Abstract][Full Text] [Related]
44. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
45. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
Wu W; Yu LH; Ma B; Xu MJ
PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
[TBL] [Abstract][Full Text] [Related]
46. Molecular mechanism of CD163
Zhang X; Wang J; Liu N; Wu W; Li H; Chen J; Guo X
Ann Transl Med; 2022 Sep; 10(18):1014. PubMed ID: 36267748
[TBL] [Abstract][Full Text] [Related]
47. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
[TBL] [Abstract][Full Text] [Related]
48. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
49. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells.
Wang Z; Xie Y; Wang H
Cancer Biol Ther; 2005 Jul; 4(7):716-9. PubMed ID: 15970709
[TBL] [Abstract][Full Text] [Related]
50. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
51. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
[TBL] [Abstract][Full Text] [Related]
52. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
Zhang TM
Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
[TBL] [Abstract][Full Text] [Related]
53. [Relationship between cytochrome c-mediated caspase-3 activity and chemoresistance in cisplatin-resistant human ovarian cancer cell lines].
Yang X; Zheng F; Xing H; Gao Q; Wang W; Lu Y; Wang S; Ma D
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):544-7. PubMed ID: 12667321
[TBL] [Abstract][Full Text] [Related]
54. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1.
Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988
[TBL] [Abstract][Full Text] [Related]
55. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
Wu Y; Wang T; Xia L; Zhang M
Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
[TBL] [Abstract][Full Text] [Related]
56. [IL-17A/lL-17RA reduces cisplatin sensitivity of ovarian cancer SKOV3 cells by regulating autophagy].
Wang L; Zhang X; Wang L; Wang B; Zhang J; Li Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Nov; 40(11):1550-1556. PubMed ID: 33243748
[TBL] [Abstract][Full Text] [Related]
57. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
58. Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
Bortot B; Mongiat M; Valencic E; Dal Monego S; Licastro D; Crosera M; Adami G; Rampazzo E; Ricci G; Romano F; Severini GM; Biffi S
Int J Nanomedicine; 2020; 15():4793-4810. PubMed ID: 32764921
[TBL] [Abstract][Full Text] [Related]
59. Long non‑coding RNA HAND2‑AS1/miR‑106a/PTEN axis re‑sensitizes cisplatin‑resistant ovarian cells to cisplatin treatment.
Li L; Li L; Hu L; Li T; Xie D; Liu X
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34476500
[TBL] [Abstract][Full Text] [Related]
60. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
